1. Home
  2. CCCC vs TLSA Comparison

CCCC vs TLSA Comparison

Compare CCCC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.42

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

BUY

Current Price

$1.56

Market Cap

200.8M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CCCC
TLSA
Founded
2015
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
240.3M
200.8M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
CCCC
TLSA
Price
$2.42
$1.56
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
1.4M
289.8K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$30,108,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.09
$0.63
52 Week High
$4.70
$2.60

Technical Indicators

Market Signals
Indicator
CCCC
TLSA
Relative Strength Index (RSI) 46.82 35.54
Support Level $2.50 $1.62
Resistance Level $2.69 $1.82
Average True Range (ATR) 0.18 0.17
MACD -0.02 -0.01
Stochastic Oscillator 10.21 30.83

Price Performance

Historical Comparison
CCCC
TLSA

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: